Qualys, Inc. (QLYS): A Bull Case Theory
We came across a bullish thesis on Qualys, Inc. (QLYS) on Substack by Na's Substack. In this article, we will summarize the bulls' thesis on QLYS. Qualys, Inc. (QLYS)'s share was trading at $126.82 as of May 5th. QLYS's trailing and forward P/E were 27.27 and 21.74 respectively according to Yahoo Finance.
Qualys, Inc. (QLYS) is a profitable, cloud-native cybersecurity company specializing in IT, security, and compliance solutions, with a foundation in vulnerability management (VM). Operating under a SaaS model, Qualys derives its recurring revenue from annual subscriptions tied to its integrated Qualys Enterprise TruRisk Platform. Over the past five years, the company has sustained high gross margins, consistent profitability, and robust free cash flow generation—hallmarks of a mature SaaS business. Despite these strengths, Qualys has experienced a noticeable slowdown in top-line growth, with a five-year revenue CAGR of 12.1% from 2019 to 2024, decelerating to 9.6% in 2024. This slowdown reflects saturation in the core VM market, rising competition, and the difficulty of sustaining high growth at scale. Nevertheless, the company has maintained GAAP operating margins consistently above 20% for much of this period and averaged FCF margins above 35% over the last three years, highlighting its ability to convert revenue into shareholder value, primarily through aggressive share repurchases.
While Qualys remains a leader in the VM space, competitive threats from specialized players like Tenable and Rapid7, alongside platform giants such as CrowdStrike and Palo Alto Networks, are eroding its market edge. To combat this, Qualys is investing in broadening its platform with offerings like TotalCloud CNAPP for cloud security and endpoint detection and response (EDR) solutions. These newer initiatives are strategically sound but still require significant traction to materially impact the company's growth profile. The challenge lies in convincing enterprises to adopt these newer modules in a crowded and rapidly evolving cybersecurity landscape dominated by larger, more diversified vendors. The TruRisk platform's integrated approach offers a potential differentiator, but success will depend on execution and product-market fit in these newer segments.
A DCF valuation that assumes growth stabilizes in the mid-single digits, while margins remain elevated, suggests an intrinsic value range of $115 to $145 per share. With shares trading around $126.75 as of late April 2025, Qualys appears fairly valued. The core investment case rests on its status as a stable, cash-generative business within cybersecurity—a sector that remains mission-critical even as growth moderates. While unlikely to deliver outsized returns from current levels, Qualys offers a compelling profile for investors seeking quality, profitability, and disciplined capital returns. Upside potential exists if newer product areas exceed expectations or strategic M&A reshapes the growth narrative. Conversely, failure to execute in these expansion areas or sustained market share loss could pressure valuation over time.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
3 hours ago
- Business Wire
ELV截止日期:Rosen Law Firm敦促損失超過10萬美元的Elevance Health, Inc. (NYSE: ELV)股東與法律事務所聯絡以瞭解有關其權利的資訊
紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球投資人權益法律事務所Rosen Law Firm提醒投資人,一名股東代表在2024年4月18日至2024年10月16日期間購買Elevance Health, Inc. (NYSE: ELV)普通股的投資人提起了集體訴訟。Elevance將自身描述為「一家為多個市場提供健康保險計畫的醫療保健公司」。 如欲瞭解更多資訊,請遞交 表格 、向Phillip Kim律師 寄送電子郵件 ,或致電866-767-3653聯絡我們。 指控內容:Rosen Law Firm正在調查對Elevance Health, Inc. (NYSE: ELV)在其業務營運方面誤導投資人的指控。 起訴書指稱,被告做出了虛假和/或誤導性陳述及/或未揭露:在醫療補助(Medicaid)重新認定程序接近完成時,被告向投資人表示,其正密切監控與重新認定程序相關的成本趨勢,且Elevance與各州協商的保費費率足以因應繼續參加醫療補助計畫病患的風險和成本狀況。儘管被告承認醫療補助支出在上升,但仍多次向投資人保證,這已充分反映在Elevance的年度指引中。這些陳述存在重大虛假或誤導性。事實上,重新認定導致Elevance醫療補助會員的疾病嚴重程度和醫療服務利用率顯著上升,因為被移出醫療補助計畫的會員平均而言比保留資格的會員更健康。這一變化的程度並未反映在Elevance與各州的費率協商中,也未體現在其2024年的財務指引裡。訴訟稱,當市場瞭解真實詳情後,投資人蒙受了損失。 現在怎麼辦:您可能有資格參與針對Elevance Health, Inc.的集體訴訟。如果有股東希望擔任該集體訴訟的原告代表,則必須在2025年7月11日之前向法院提出申請。原告代表是指代表其他集體訴訟成員主導訴訟的當事人代表。您無需參與此案即有資格獲得追償。如果您選擇不採取任何行動,您也可以保持缺席集體訴訟成員的身分。如欲瞭解更多資訊,請點選 此處 。 所有代理均為勝訴後取酬。股東無需支付任何費用或開支。 關於Rosen Law Firm:與Rosen Law Firm不同,一些就此等事宜發表公告的法律事務所並不會實際提起證券集體訴訟。身為股東權益訴訟領域公認的領導者, Rosen Law Firm 一直致力於協助股東挽回損失、改善公司治理結構,並追究公司高階主管的違法行為責任。自成立以來,Rosen Law Firm已經為股東挽回了超過10億美元的損失。 請在LinkedIn: 、Twitter: 或Facebook: 上關注我們,以瞭解最新情況。 律師廣告。先前案例不保證可獲致類似結果。 免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。


Business Insider
3 hours ago
- Business Insider
Rubrik, Inc. Class A (RBRK) Receives a Buy from Citi
In a report released on June 27, Fatima Boolani from Citi maintained a Buy rating on Rubrik, Inc. Class A (RBRK – Research Report), with a price target of $117.00. The company's shares closed last Friday at $87.38. Don't Miss TipRanks' Half Year Sale Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Boolani covers the Technology sector, focusing on stocks such as Cloudflare, Check Point, and Fortinet. According to TipRanks, Boolani has an average return of 21.1% and a 66.38% success rate on recommended stocks. Rubrik, Inc. Class A has an analyst consensus of Strong Buy, with a price target consensus of $111.06, which is a 27.10% upside from current levels. In a report released on June 25, Robert W. Baird also maintained a Buy rating on the stock with a $110.00 price target. RBRK market cap is currently $16.91B and has a P/E ratio of -30.76. Based on the recent corporate insider activity of 118 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RBRK in relation to earlier this year. Earlier this month, Enrique Salem, a Director at RBRK sold 700,000.00 shares for a total of $63,763,000.00.


Business Wire
a day ago
- Business Wire
WST截止日期:Rosen Law Firm敦促損失超過10萬美元的West Pharmaceutical Services, Inc. (NYSE: WST)股東與法律事務所聯絡以瞭解有關其權利的資訊
紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球投資人權益法律事務所Rosen Law Firm提醒投資人,一名股東代表在2023年2月16日至2025年2月12日期間購買West Pharmaceutical Services, Inc. (NYSE: WST)證券的投資人提起了集體訴訟。West將自身描述為一家「專注於注射藥物包裝元件、密封解決方案及輸送系統的醫療用品公司」。 如欲瞭解更多資訊,請遞交 表格 、向Phillip Kim律師 寄送電子郵件 ,或致電866-767-3653聯絡我們。 指控內容:Rosen Law Firm正在調查對West Pharmaceutical Services, Inc. (NYSE: WST)在其業務營運方面誤導投資人的指控。 起訴書指稱,在整個集體訴訟期內,被告做出了虛假和誤導性陳述及/或未揭露:(1)儘管聲稱對客戶需求有清晰預判,並將業務阻力歸咎於COVID相關產品的臨時性去庫存,但West實際上在其高利潤率的高價值產品(HVP)組合中持續經歷著顯著的去庫存現象;(2) West的SmartDose裝置雖被標榜為高利潤率的成長型產品,但由於營運效率不彰,對West的利潤率造成了嚴重稀釋;(3)這些利潤率壓力引發了高昂重整活動的風險,包括West退出與長期客戶簽署的持續血糖監測(CGM)合約;以及(4)由於上述原因,被告關於West的業務、營運和前景的正面陳述具有重大誤導性和/或缺乏合理依據。訴訟稱,當市場瞭解真實詳情後,投資人蒙受了損失。 現在怎麼辦:您可能有資格參與針對West Pharmaceutical Services, Inc.的集體訴訟。如果有股東希望擔任該集體訴訟的原告代表,則必須在2025年7月7日之前向法院提出申請。原告代表是指代表其他集體訴訟成員主導訴訟的當事人代表。您無需參與此案即有資格獲得追償。如果您選擇不採取任何行動,您也可以保持缺席集體訴訟成員的身分。如欲瞭解更多資訊,請點選 此處 。 所有代理均為勝訴後取酬。股東無需支付任何費用或開支。 關於Rosen Law Firm:與Rosen Law Firm不同,一些就此等事宜發表公告的法律事務所並不會實際提起證券集體訴訟。身為股東權益訴訟領域公認的領導者, Rosen Law Firm 一直致力於協助股東挽回損失、改善公司治理結構,並追究公司高階主管的違法行為責任。自成立以來,Rosen Law Firm已經為股東挽回了超過10億美元的損失。 請在LinkedIn: 、Twitter: 或Facebook: 上關注我們,以瞭解最新情況。 律師廣告。先前案例不保證可獲致類似結果。 免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。